{
  "docId": "019de076-f8dc-71cb-8c77-d8d892e68e05",
  "docSlug": "d63a60a343bcaadeb9fd5627a42c66c9",
  "documentTitle": "CARGO Therapeutics | IPO Presentation Deck | 29 slides",
  "authorId": "cargo-therapeutics",
  "authorName": "CARGO Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 16,
  "pageCount": 29,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide outlines the methodology for a clinical trial, specifically detailing the patient population and treatment protocol.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/16",
  "deckHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05",
  "deckJsonHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json",
  "deckAnchorHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Abbreviations: R/R = relapsed or refractory; FL = follicular lymphoma; PMBCL = primary mediastinal large B cell lymphoma; HGBCL = high-grade B-cell lymphoma; PET/CT = positron emission tomography / computed tomography; ORR = overall response rate; DOR = duration of response; PFS = progression free survival; OS = overall survival",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d10eb5d4-3301-48a8-940f-6e702da93546",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.2,
        "x": 0.73,
        "y": 0.2
      },
      "kind": "list",
      "text": "Endpoints: Primary (ORR per PET/CT), Secondary (ORR, CR, DOR, PFS/OS, Safety)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88cd86c6-1ee2-480f-81a8-869d52c2e396",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.2,
        "x": 0.27,
        "y": 0.2
      },
      "kind": "list",
      "text": "Cohort 1: Prior CD19 CAR T-cell therapy (n=81); Cohort 2: Nonconforming product or dose; Cohort 3: Prior Bispecific Abs (n=20)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4c632a9-84bf-46e3-a621-afa403cf1735",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.2,
        "x": 0.5,
        "y": 0.2
      },
      "kind": "list",
      "text": "Conditioning chemotherapy: Fludarabine 30 mg/m2 IV, Cyclophosphamide 500 mg/m2 IV, Target CRG-022 cell dose 1 x 10^6 viable CAR+ cells/kg",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1bbd2e0-9bcb-47de-b98f-cae742e70507",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.2,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Key eligibility criteria: R/R LBCL (DLBCL, Transformed FL, PMBCL, HGBCL), CD22 expression",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "daf06c3c-49ab-40d8-98b3-d456b7f17bf2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Potentially pivotal Phase 2 clinical trial of CRG-022 in R/R LBCL",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6aee9de8-91f2-47a9-a45d-eb6ae671f2cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "Currently enrolling",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42912c23-f0a3-4c9f-8656-65abc3b0e30c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 28,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97",
      "evidence": "The loop is opened on slide 4 and closed on slide 28",
      "position": 1,
      "objective": "Why does CARGO Therapeutics exist? What is the company's vision?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}